Molbio Diagnostics Ranks Second in September with 1.5 billion Dollars in Unicorn Valuation: Reports
We are here in the last quarter of 2022, and the Indian start-up arena has readily included 23 fresh entrants to the coveted 1 billion dollars valuation team.
Recently, Molbio which is a renowned healthcare diagnostic firm
announced on Monday, that it made an 85 million dollar round led by Temasek.
Molbio is a firm based in goa, which received its first-ever tranche from
investors based in Singapore through V sciences investments at a recently held
unicorn valuation.
This year our country has viewed new unicorns which are emerging
across different sectors along with the all-new entrant in the list Molbio
Diagnostics, they are such as Fractal, Darwinbox, LEAD, Polygon, DealShare,
Expressbees, Amagi, Purplle, Physics Wallah, Leadsquare, OneCard to name a few.
These are the news related to the best start-ups for 2022.
According to a report published in PwC, there are over more than
50 Indian startups
that have the potential to make entry into the unicorn club.
Molbio diagnostics is known for its molecular diagnostic testing
platform. It will be the 108th unicorn which will come after Tata 1mg which is
being listed in the same earlier this month.
According to a report, Molbia would use these funds to maximize
its global network. Presently Molbio diagnostics Pvt. Ltd chain operators are
present in more than 40 countries. The chief executive officer and diagnostics
director of Molbio, Mr Sriram Natarajan said in an interview with VCCircle that
it also aims to expand its presence further adding at least 20 to 25 countries
each year.
Molbio diagnostic pvt. Ltd product Truenat provides IoT-enabled
testing kits to test more than 40 diseases including COVID-19, HIV, HPV, hepatitis,
dengue, chikungunya, malaria, etc. the platform can help provide results within
an hour at an economical price view.
As per the yearly financial statements with the Registrar of
Companies (RoC), Molbio’s collection from operation raised to INR1272 crore as
compared to 51.53 crore rupees in FY20. The company this year will earn around
rupees 850 crores in FY22 as the demand for coronavirus testing kits has
increased after FY21.
However, the unicorn
startup aims to be a one-billion-dollar revenue company within the next 3 to 5
years by selling surveillance platforms for different types of diseases around the globe.

Comments
Post a Comment